Print

Immunotherapy dostarlimab gains FDA approval for treatment of recurrent and advanced endometrial cancer

https://www.facingourrisk.org/XRAY/dostarlimab-for-advanced-endometrial-cancer
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer

The FDA has given accelerated approval for the immunotherapy agent dostarlimab (Jemperli) to treat recurrent and advanced endometrial cancer that has a biomarker called mismatch repair deficiency (dMMR). This adds a new treatment option for people with recurrent or advanced endometrial cancer. (posted 5/18/21)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following studies are enrolling people with advanced endometrial cancer.  

Several other clinical trials for patients with endometrial cancer can be found here.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.